ArticleScientific reports2025
Differential expression of glucose metabolism and circadian rhythm-related genes in patients with acute myocardial infarction and their clinical significance.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Circadian control of immune homeostasis in cardiovascular health and disease.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Acute myocardial infarction (AMI) is a leading cause of mortality worldwide, with about 7 million deaths annually from cardiovascular disease. Current diagnostic and therapeutic approaches face challenges, highlighting the need for new biomarkers and diagnostic methods. Abnormalities in glucose metabolism and circadian rhythm genes are linked to cardiovascular conditions, and understanding these mechanisms may reveal new therapeutic targets. This study aimed to identify differentially expressed genes related to glucose metabolism and circadian rhythms (GMCRRDEGs) in AMI. Bioinformatics techniques, including differential expression analysis, enrichment analysis, and machine learning models, were used to find prospective biomarkers for early diagnosis and therapeutic intervention. Twelve GMCRRDEGs were found, with six key genes (JUN, EPAS1, IL1B, ADRB2, FOS, CD36) incorporated into the diagnostic model, showing high accuracy in both the training set (AUC = 0.93) and validation set (AUC = 0.91). Enrichment analysis linked GMCRRDEGs to biological processes related to NO synthesis and tumor necrosis factor signaling pathways. Immune infiltration analysis showed significant changes in immune cell abundance, especially in mast cells and neutrophils, among high-risk patients. This study highlights GMCRRDEGs as AMI biomarkers, emphasizing their role in disease mechanisms and immune responses. Further research should validate these findings in larger cohorts to enhance early detection for AMI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.